Composite magnetic nanoparticles ͑MNPs͒ consisting of an MNP core and drug loaded polymer shell can increase the efficacy of cancer therapy by overcoming several limitations of conventional hyperthermia and chemotherapy. Multimodal therapy consisting of simultaneous hyperthermia and chemotherapy can increase therapeutic efficiency compared to individual applications of these modalities. Factors influencing power output in an alternating magnetic field ͑AMF͒ for superparamagnetic ␥-Fe 2 O 3 and Fe 3 O 4 iron oxide MNP were studied. The optimum MNP properties for in vivo magnetic hyperthermia were identified. For a 375 kHz AMF, 23 nm ␥-Fe 2 O 3 MNP and 12 nm Fe 3 O 4 MNP produce maximum heating, heat generation is dependent primarily on Néel relaxation and is insensitive to polymer shell thickness. The heating of tumors by uniformly distributed magnetic clusters of optimized iron oxide MNP was modeled. The MNP mass required to heat tumors to hyperthermia temperatures was calculated, the Fe 3 O 4 MNP concentration in the tumor required for hyperthermia was in the range of 0.12-2.2 g ml −1 for Fe 3 O 4 and 0.06-1.7 g ml −1 for ␥-Fe 2 O 3 MNP respectively. In vitro drug release from doxorubicin loaded poly-n-isopropylacrylamide coated MNP was also modeled to understand the influence of shell thickness on thermoresponsive drug release. An increase in shell thickness or decrease in temperature resulted in decreased drug release rates. The MNP mass requirements for hyperthermia closely match the requirements for chemotherapy confirming the feasibility of these particles for combined hyperthermia and drug release applications.
I. INTRODUCTION
Conventional chemotherapy and hyperthermia treatment of cancer suffers from several drawbacks that reduce therapeutic efficiency and cause undesirable side effects. In chemotherapy, powerful cytotoxic drugs kill cancer cells; however, conventional parenteral administration causes systemic drug distribution resulting in systemic toxicity, death of healthy cells, serious side effects, 1 and insufficient drug concentration in the tumor. Hyperthermia involves selective deactivation of cancer cells by heating in the temperature range of 41-47°C ͑Refs. 2 and 3͒ but conventional hyperthermia techniques suffer from insufficient temperature rise in the tumor, poor temperature distribution and risk of organ damage due to overheating. 3, 4 Iron oxide magnetic nanoparticles ͑MNPs͒ can improve cancer therapy by overcoming several limitations of conventional chemotherapy and hyperthermia. Composite nanoparticles ͑CNP͒ consisting of an iron oxide core and polymer shell can be loaded with cytotoxic drugs, dispersed in a carrier fluid, injected into the bloodstream, and targeted to the tumor using an external magnetic field gradient.
5-12 These particles release the drug following localization in the tumor, resulting in increased tumor drug concentration with minimal systemic toxicity. If an alternating magnetic field ͑AMF͒ is applied after localization, the iron oxide magnetic cores of the particles generate heat, raising the temperature of the tumor and resulting in hyperthermia. 4, 6, [13] [14] [15] [16] [17] [18] Multimodal cancer therapy, consisting of simultaneous hyperthermia and chemotherapy has a synergistic effect and can enhance therapeutic efficiency compared to individual or sequential applications of these modalities. 3, [19] [20] [21] [22] [23] [24] [25] [26] [27] Clinical trials for magnetic drug targeting 10, 28 as well as magnetically mediated hyperthermia 14, 17, [29] [30] [31] have been conducted with promising results.
We have previously reported in vitro simultaneous hyperthermia and drug release studies using doxorubicin loaded thermoresponsive poly-n-͑isopropylacrylamide͒ ͑PNIPAM͒ coated ␥-Fe 2 O 3 ͑Ref. 12͒ and Fe 3 O 4 CNP. 32 Doxorubicin loading of ϳ4 wt % of the CNP was achieved; under hyperthermia conditions ϳ36% of the loaded drug was released in vitro. 32 Drug loaded CNP were also successfully targeted to liver tumors in a rat model in vivo. 12, 33 Thus these particles show great promise for combined hyperthermia and drug release applications. Modeling of power generation from MNP in an AMF ͑Refs. 18 and 34-37͒ as well as tumor heating by MNP ͑Refs. 38-46͒ has been previously reported. The current work studies the effect of selected particle properties such as magnetic particle size, hydrodynamic diameter, anisotropy constant, and AMF parameters on heat generation in MNP to identify the optimum parameters for hyperthermia from drug a͒ Electronic mail: ramanujan@ntu.edu.sg. FAX: ͑65͒ 67909081. Tel.: ͑65͒ 67904342.
loaded polymer coated MNP. MNP clusters are assumed to be uniformly distributed in the tumor and heat up surrounding tumor tissue on a microscopic scale, the sum of these volumes is the hyperthermia coverage of the whole tumor ͓Figs. 1͑a͒ and 1͑b͔͒. This model predicts the mass of iron oxide required for full hyperthermia coverage for various tumor sizes as well as the thermal coverage for a specified minimum tissue temperature. The MNP mass requirements for hyperthermia is compared with that of drug loaded CNP for chemotherapy to determine the feasibility of combined hyperthermia and drug delivery. In vitro drug release from CNPs consisting of an iron oxide core and poly-n͑isopropylacrylamide͒ shell at hyperthermia temperature is also modeled.
It was found that AMF field strength and frequency as well as particle properties such as particle size and anisotropy constant strongly influence power output; the highest power output is obtained in a relatively narrow particle size range. Optimum particle sizes for in vivo tumor heating were identified, optimum sized ␥-Fe 2 O 3 MNP produce higher power output than optimum sized Fe 3 O 4 MNP. Hyperthermia in a tumor strongly depends on AMF strength and mass of MNP distributed in the tumor. MNP mass requirements for hyperthermia and chemotherapy are similar, confirming the feasibility of these particles for combined hyperthermia and chemotherapy applications.
II. METHODOLOGY

A. Power output from MNPs exposed to an AMF
Heat generation from MNP exposed to an AMF occurs primarily by hysteresis losses and relaxation losses; the dominant mechanism is determined by particle size and AMF parameters. 13, 18 Superparamagnetic MNP can exhibit hysteresis loops in an AMF depending on the frequency, 47 however for clinically relevant AMF parameters, the primary loss mechanisms are relaxational. Since power output is sensitive to particle properties and AMF parameters, it is essential to study the effect of these factors on heat generation in polymer coated MNP and the tumor heating using such particles. A model for heat generation from superparamagnetic MNP ferrofluids has been previously proposed by Rosensweig. 18 When the external field applied to a ferrofluid is reduced to zero, its magnetization decreases to zero due to ambient thermal energy; this relaxation can be Brownian or Néel and occurs rapidly as the AMF varies between positive and negative values of its maximum amplitude. In Néel relaxation, the magnetic moment of the particle rotates internally to align with the field while in Brownian relaxation, the particle physically rotates to align the moment with the field. The relaxation processes are characterized by relaxation times. For Brownian relaxation, the relaxation time B is given by 
where is the viscosity of the fluid, T the temperature, and V H the hydrodynamic volume of the particle. The Néel relaxation time N is given by
where K is the anisotropy constant, V M is the magnetic volume, and 0 =10 −9 s. Since Brownian and Néel relaxation processes occur in parallel, the effective relaxation time is given by
The shorter relaxation time term dominates the effective relaxation time for a given particle size. B is determined in part by the hydrodynamic properties of the fluid, while N is governed by the magnetic anisotropy energy relative to thermal energy. Both Brownian and Néel processes may be present in a ferrofluid but only Néel relaxation occurs in constrained ͑i.e., immobilized͒ superparamagnetic particles. The volumetric power dissipation can be expressed as
where 0 is the permeability of free space, 0 is the equilibrium susceptibility, H 0 is the AMF field strength, and f is the AMF frequency. 0 can be calculated from the following expressions:
where is the volume fraction of nanoparticles in the ferrofluid and M d is the domain magnetization of the nanoparticle. Experimentally, quantification of heat generation from magnetic particles is given by the specific absorption rate ͑SAR͒ which can be calculated as
where C is the mass weighted heat capacity of the ferrofluid and ͑⌬T / ⌬t͒ is the slope of the initial section of the temperature versus time curve. The Rosensweig model 18 was used to examine the effect of particle size on the heating power ͑SAR͒ of polymer coated ␥-Fe 2 O 3 and Fe 3 O 4 nanoparticles in a ferrofluid exposed to an AMF. The nanoparticles were assumed to be monodisperse and spherical, the hydrodynamic diameter ͑D H ͒ was taken to be the magnetic particle diameter ͑D M ͒ for MNP and the particle diameter for CNP except where stated. The analysis does not incorporate polydispersity, viscous and hysteresis losses, interparticle interactions, and changes in viscosity with temperature. The materials properties are listed in Table I .
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B. Modeling of tumor heating from optimized iron oxide nanoparticles
The temperature rise and thermal coverage of tumors from AMF induced heating of MNP was modeled to determine the quantity of MNP required to raise tumor temperatures to hyperthermia levels. The following methodology was used.
• Tumors were assumed to be spherical with uniform distribution of CNP clusters in the tumor volume ͓Fig. 1͑a͔͒.
• Upon AMF application, a MNP cluster acts as a point heat source and heats up the surrounding tissue. The equation for heat conduction from a point source in a spherical volume ͓Eq. ͑9͔͒ ͑Ref. 48͒ was used to calculate the temperature rise in the tumor after heating for 30 min for a range of power values of the point source. The maximum temperature in the tissue at a microscopic distance of 80 m from the point heat source was fixed at thermoablative levels of 60°C.
The point heat source model deviates from real-world behavior as the distance from the point source decreases to small values, hence a distance of 80 m from the point source was chosen for fixing maximum tumor tissue temperature. Assuming a typical cell size of ϳ10-20 m, 46 this corresponds to a distance of ϳ4 -8 cells from the point source. The following equation was used to model the temperature distribution in the region surrounding the point heat source:
where T r is the temperature at distance r from the point source, T ϱ is the steady state temperature at the boundary of the localized spherical volume, Q is the power output from the MNP cluster point source, k t is the thermal conductivity of the tumor tissue, the thermal diffusivity ␣ = ͑k t / t C t ͒, t is the density of tumor tissue, C t is the specific heat capacity of the tumor tissue, and t is the time. The values used are listed in Table II. • Using Eq. ͑9͒, the power output from a single point source required to heat tumor tissue in the temperature range of 42-60°C in 30 min was determined to be 12.5 mW by an iterative method. The temperature profile is shown in Fig. 1͑b͒ . • Using Eq. ͑9͒, the radius corresponding to Ն42°C temperature coverage in the tumor from this 12.5 mW source was calculated to be 350 m ͓Fig. 1͑b͔͒. The change in temperature with time at various distances from the point source was also calculated using Eq. ͑9͒ ͓Fig. 1͑c͔͒.
• The mass of MNP clusters required at each point source to achieve the required power output of 12.5 mW was calculated on the basis of the SAR of the MNP. Particle sizes yielding maximum SAR were used for this calculation, i.e., 23 nm for ␥-Fe 2 O 3 and 12 nm for Fe 3 O 4 ͑Sec. III͒. • For clinically relevant 14, 30 quantities ͑0.5-4 g͒ of MNP distributed uniformly in the tumor, the microscopic volume heated to a minimum temperature of 42°C by each point source was summed to obtain the total tumor volume at hyperthermia temperatures.
• The volume corresponding to the total mass of MNP was subtracted from the overall tumor volume to yield the effective tumor volume heated by the MNP. The tumor volume at hyperthermia temperatures was divided by the effective tumor volume to obtain the fraction of tumor volume experiencing hyperthermia.
C. Modeling of drug release from doxorubicin loaded PNIPAM-iron oxide CNPs
The drug release from dox loaded iron oxide-PNIPAM CNPs at 24, 37, and 43°C was modeled for different particle sizes using experimental data 32 from drug release tests. The following methodology and assumptions were used.
• Drug loaded CNPs were assumed to be spherical and monodisperse. The experimentally measured hydrodynamic diameter of 158 nm ͑Ref. 32͒ was taken as the particle diameter.
• Drug release was diffusion controlled, the diffusion coefficient D dox was determined by fitting experimental data to the equation for drug release ͓Eq. ͑10͔͒ from a monolithic spherical particle.
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where M t , is the cumulative mass of drug released in time t, M ϱ is the cumulative mass of drug released at infinite time ͑taken as the total drug loading of the particles͒, and R is the radius of the CNP. The calculated D dox values for each cumulative release period t and the related M t / M ϱ values were used in Eq. ͑10͒ to calculate the corresponding release times for particles of various sizes. Using the materials properties listed in Table I , typical attempt time scale 0 of 10 −9 s and observational time scale of 100 s, the superparamagnetic size limit can be calculated 52 as 14-17 nm for Fe 3 O 4 MNP and 28 nm for ␥-Fe 2 O 3 MNP. In the superparamagnetic regime, at low AMF frequencies ͑f Ӷ 1͒, power output increases as the square of the frequency. When ft ӷ 1, the power loss is insensitive to frequency, the maximum power output occurs when f =1, 13 for e.g., of a 13 nm Fe 3 O 4 MNP is 1.65ϫ 10 −6 s, increasing f beyond 606 kHz will not significantly increase SAR. For simultaneous hyperthermia and drug release applications, a polymeric surface coating around the MNP is essential, this coating will increase D H . After synthesis of MNP and coating with polymer, it is likely that the MNP will be present as clusters encapsulated in the polymer, or bare MNP clustered together due to interparticle magnetic or other in- 18, 35 and experimentally studied. 35, 36 The importance of heating by Néel relaxation has been highlighted by other researchers, [34] [35] [36] [37] and their conclusions support our results. Gazeau et al. studied the effects of field parameters and materials properties on the SAR of ␥-Fe 2 O 3 and CoFe 2 O 4 MNP; 35 optimum particle size for maximum SAR shifted to smaller sizes for MNP with higher K. Brownian heating was available from a broader range of particle sizes, however, Néel heating within the narrow optimum size range produced substantial heating. Néel heating from larger MNP produced higher SAR compared to smaller particles; this is also clearly predicted in the current work where Néel heating of larger ␥-Fe 2 O 3 MNP ͑23 nm͒ yielded higher SAR than smaller Fe 3 O 4 MNP ͑12 nm͒ ͑Fig. 6͒. Importantly, the same group also demonstrated that once the MNP are internalized by cells, heating occurs almost exclusively by Néel relaxation. for 0.06 g ml −1 dropping to 4 kA m −1 for 0.3 g ml −1 ͓Fig. 7͔. As tumor size increases, increasing either the MNP mass or the applied AMF field strength can maintain hyperthermia temperatures ͓Figs. 8͑a͒ and 8͑b͔͒. For instance, 0.5 g of Fe 3 O 4 MNP fully heats up a 1.5 cm tumor when exposed to 11 kA m −1 , increasing MNP mass to 1 g the same heating can be achieved with ϳ7 kA m −1 ͓Fig. 8͑a͔͒. Since their SAR is higher, tumors can be heated with lower concentrations of ␥-Fe 2 O 3 MNP than that of Fe 3 O 4 MNP ͓Fig. 8͑b͔͒. Additionally, field strength and MNP mass requirements decrease significantly as target temperature is reduced ͓Fig. 9͔. The temperature at the tumor boundary should not exceed 42°C to prevent damage to healthy tissue surrounding the tumor. The safety requirement of a maximum temperature of 42°C at the tumor boundary is included in the present work by explicitly limiting the temperatures of the localized spherical volume heated by the point source in the range of 42-60°C. At the tumor boundary, outside this "localized hyperthermia volume" ͑r Ͼ 350 m͒, the temperature is below 42°C ͓Fig. 1͑b͔͒ and decreases to 37°C, hence blood perfusion effects in this region are implicitly accounted for by the 37°C boundary temperature.
III. RESULTS AND DISCUSSION
A. Power generation from MNPs in an AMF
In previous work, Rabin showed that intracellular hyperthermia was not feasible when MNP clusters are embedded in a single cell ͑size 10-20 m and surrounded by a large cellular network of MNP-free cells. 46 In the current model, the uniform distribution of MNP clusters and localized volume of tumor heated by each MNP cluster is used to determine thermal coverage of the tumor ͓Fig. 1͑a͔͒. Andrä et al. 43 modeled the spatial distribution of temperature in a tumor from hysteresis heating of micron sized magnetic particles. Dughiero et al. 41 used a finite element model to calculate temperature rise in tumors containing different concentrations of MNP with optimized particle size and 300 kHz, 3.3 kA m −1 AMF. For 15 nm MNP and 3 wt % concentration, the temperature in a 3 cm tumor after 7 min of heating was 51.4°C, at the boundary of the tumor the temperature rapidly dropped to 42°C.
McHenry and co-workers 53 modeled the volumetric power loss from Fe 3 O 4 , ␥-Fe 2 O 3 , Fe, FePt, Co, and FeCo in a 300 kHz, 39.7 kA m −1 AMF using the Rosensweig model. FeCo was found to yield the highest power output. It was suggested that the cobalt ferrite shell on the FeCo particles would provide a stable, biocompatible surface. Self- regulated heating of ferrofluids with temperature dependent magnetization and anisotropy was also studied. They also modeled heating of a 10 ml ͑r = 2.15 cm͒ tumor with FeCo MNP ferrofluid in a 267 kHz, 29.8 kA m −1 AMF using analytical and finite element methods 45 and predicted that temperatures inside the tumor would reach thermoablation levels ͑⌬T ϳ 30°C in 110 s͒ while the edges would undergo hyperthermia.
In human clinical trials 14,30 a ferrofluid containing aminosilane coated 15 nm core MNP was used for tumor volumes ranging from 1.8 to 49.8 ml; the frequency was 100 kHz and the highest tolerated field strength was greater than 10 kA m −1 ͑in the head region͒. For an average MNP concentration of ϳ64 mg ml −1 in tumor tissue, full hyperthermia coverage greater than 42°C was achieved only in ϳ30% of the tumors, while 40°C coverage was achieved in more than 90% of tumors. 30 The authors suggested that increasing the field strengths would improve heating. This is consistent with our observations that for a given mass of MNP, hyperthermia coverage can be increased in a tumor by increasing field strength.
C. Dox release from polymer-iron oxide CNPs
The predicted dox release profiles for iron oxide-PNIPAM CNP in PBS for various particle sizes at 24, 37, and 43°C based on experimental data 32 indicate that release occurs faster at higher temperatures. An initial burst release phase is seen, followed by slower, steady state release. The burst release phase becomes less prominent as particle size increases and overall drug release also becomes slower. The rate of drug release at hyperthermia and body temperatures as well as the amount of drug loaded onto the CNPs can be tuned by modifying the thickness of the polymer coating. This provides flexibility in drug dosage without adversely affecting heat generation when the magnetic core consists of MNP with Néel relaxation optimized particle sizes.
For clinical chemotherapy, dox dosage administered intravenously every three weeks is based on body surface area of the patient and is in the range of 60-75 mg m −2 . 54 However, with magnetic drug targeting, equivalent chemotherapeutic effect can be achieved with doses as low as 20%-50% of the conventional dose. 7 For a patient of height 160 cm and weight 55 kg, body surface area can be calculated as 1.56 m 2 using the Mosteller formula. 55 Assuming a 70 mg m −2 dox dosage, the quantity of dox required for intravenous administration is ϳ110 mg. Conservatively assuming 50% of this dosage for equivalent therapeutic efficiency in magnetic targeting and 4 wt % dox loading of the CNP, the quantity of CNP required is 1375 mg. Making another conservative assumption that only 75% of the CNP reach the targeted tumor, the total quantity of CNP required for magnetic targeting is ϳ1835 mg ͑the actual quantity of drug loaded CNP required is likely to be lower, especially for smaller tumors͒. The mass of MNP required for hyperthermia of tumors smaller than ϳ2 cm ͑Fig. 8͒ with clinically relevant AMF parameters is in the same range ͑ϳ2 g͒ as that required for MDT. These calculations show that the quantity of dox loaded CNP required for hyperthermia and chemotherapy treatments match closely, increasing the feasibility of these particles for combined hyperthermia and drug release applications. For large tumors that require higher mass of MNP for hyperthermia, drug loading of the particles can be tuned as per the dosage requirements for chemotherapy.
IV. CONCLUSIONS
The current work identified the properties of iron oxide MNP needed for in vivo tumor heating, the MNP mass requirements for hyperthermia in tumors of various sizes and the MNP mass requirements for simultaneous hyperthermia and chemotherapy. Power output from iron oxide nanoparticles was modeled and optimum particle sizes were determined. These optimum particle sizes were used to model tumor heating for hyperthermia in a tumor containing uniformly dispersed MNP clusters.
• For 375 kHz AMF frequency, optimum particle size for Fe 3 O 4 particles is in the 12-13 nm range and for ␥-Fe 2 O 3 particles is in the 23-24 nm range. For such particle sizes heating power will not decrease when the particles are immobilized in tumor cells. Increase in shell thickness due to polymer coating will also not adversely affect heat generation since Néel relaxation is the primary heat generation mechanism, ␥-Fe 2 O 3 nanoparticles generate more heat than Fe 3 O 4 nanoparticles.
• Tumors can be heated up to hyperthermia temperatures by increasing either nanoparticle concentration in the tumor or by increasing AMF strength. MNP concentration in the tumor required for hyperthermia coverage were in the range of 0.06-1.7 g ml −1 and 0.12-2. • Modeling of dox release from dox loaded PNIPAMiron oxide particles shows that dox release occurs faster with increase in temperature as well as with decrease in polymer shell thickness, therefore release rate can be controlled by changing the shell thickness. The mass of particles required for hyperthermia and chemotherapy are similar, favoring the use of these particles for combined hyperthermia and chemotherapy applications. 
